Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

Trial Profile

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trofinetide (Primary)
  • Indications Rett syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms DAFFODIL
  • Sponsors Acadia Pharmaceuticals

Most Recent Events

  • 05 Mar 2025 Results presented in an Acadia Pharmaceuticals Media Release.
  • 05 Mar 2025 According to an Acadia Pharmaceuticals media release, results of DAFFODIL, LAVENDER, LILAC-1 and LILAC-2 studies supported the FDA approval of DAYBUE in adults and pediatric patients two years of age or older.
  • 05 Mar 2025 According to an Acadia Pharmaceuticals media release, results of this study published in the journal Med.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top